HDAC1/2 maintain TERT mRNA stability in TERT-rearranged neuroblastoma
In the authors' words
Genomic TERT locus rearrangements define an aggressive high-risk neuroblastoma subgroup characterized by enhancer hijacking, high-level TERT expression and continuous telomerase activation. Although these structural alterations supply a strong transcriptional drive, the post-transcriptional mechanisms preserving TERT mRNA presence remain incompletely understood. We identified histone deacetylases 1 and 2 (HDAC1/2) as essential post-transcriptional guardians of TERT mRNA stability in TERT-rearranged neuroblastoma. Pharmacological inhibition or RNAi-mediated depletion of HDAC1 and HDAC2, but not HDACs 3-11, rapidly downregulated TERT transcript levels and suppressed telomerase enzymatic activity. Transcript decay kinetics following transcriptional arrest with actinomycin D confirmed that HDAC1/2 blockade accelerates TERT mRNA decay, reducing transcript half-life by 30-47%. High-resolution ChIP-seq profiling across the translocation breakpoint demonstrated HDAC inhibition does not alter local chromatin accessibility. Array-based DNA methylation profiling showed only a mild, non-specific global reduction in CpG island methylation upon panobinostat exposure and no focal correlation with TERT transcript loss across the breakpoint locus. Depleting TERT mRNA via HDAC1/2 inhibition dismantled a core 50-gene TERT-associated oncogenic expression network. Ectopic re-expression of TERT cDNA partially rescued cellular viability and normalized expression of key signature genes despite continuous HDAC inhibition. HDAC1/2 inhibition significantly attenuated tumor growth, reduced intratumor TERT expression and prolonging overall survival in both preventive and therapeutic TERT-rearranged xenograft mouse models. Our data establish a post-transcriptional rather than transcriptional mode of TERT regulation and confirm tumor suppression is partly driven by depleting TERT transcripts, uncovering a HDAC1/2 dependency in TERT-driven neuroblastoma. We provide a molecular rationale for therapeutic strategies disrupting HDAC1/2-mediated TERT mRNA stabilization.
Appeared: Wednesday, November 18. bioRxiv. Preprint, not yet peer-reviewed.